Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147622 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| Hydrochloric Acid SCHEMBL30744256 | 0.99 | MDM2 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL19061181 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31370642 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL17995306 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL23336308 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL12972288 | 0.91 | MDM2 (0.50) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL19130178 | 0.91 | KMT2A (0.50) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL15305865 | 0.91 | KMT2A (0.50) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL8892538 | 0.91 | MDM2 (0.60) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965889-B2 | Lysine monomethylated derivative and corresponding antibody and use thereof | PMT BIOLABS INC (CN) | 2024-04-23 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20170146550-A1 | Alysine Monomethylated Derivative and Corresponding Antibody and Use Thereof | PMT BIOLABS INC (CN) | 2017-05-25 | — | — | US | disclosed |
| WO-2016011920-A1 | ALYSINE MONOMETHYLATED DERIVATIVE AND CORRESPONDING ANTIBODY AND USE THEREOF | PMT BIOLABS INC (CN) | 2016-01-28 | — | — | WO | disclosed |
| US-20130065248-A1 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE | CORNELL UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965889-B2 | Lysine monomethylated derivative and corresponding antibody and use thereof | KMT5A, PTMS, KDM4D | MDM2 1067/4885MDM4 526/4885TP53 2120/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MDM2 942/4885MDM4 1294/4885TP53 42/4885 |
| US-20170146550-A1 | Alysine Monomethylated Derivative and Corresponding Antibody and Use Thereof | PTMS, KDM7A, KMT5A | MDM2 1898/4885MDM4 994/4885TP53 2576/4885 |
| US-20130065248-A1 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE | SIRT3, SIRT1, SIRT2 | MDM2 726/4885MDM4 2430/4885TP53 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.